SFC Fluidics

Executive Summary

SFC Fluidics is a privately held medical device company based in Fayetteville, Arkansas, focused on developing advanced drug delivery systems using its proprietary microfluidic platform. The company's lead product, the PANDA™ patch pump, is designed to simplify and improve insulin delivery for diabetes management, offering a discreet, wearable alternative to traditional insulin pumps. The platform's versatility also holds potential for delivering therapeutics in other disease areas, including cancer and chronic pain. Since its founding in 2009, SFC Fluidics has concentrated on refining its microfluidic technology to enhance reliability, precision, and patient comfort. The PANDA pump aims to address key limitations of current insulin delivery devices, such as occlusion, dosing inaccuracies, and user complexity, potentially improving adherence and outcomes for diabetic patients. With a strong IP portfolio and a clear focus on the large and growing diabetes market, SFC Fluidics is positioned to compete with established players like Insulet and Medtronic.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for PANDA™ Patch Pump60% success
• Q4 2026Strategic Partnership with Major Insulin Manufacturer45% success
• TBDExpansion of Microfluidic Platform into Oncology Indication30% success